{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health&answer.previousAnswerVersion.answeringMemberConstituency=Mid+Norfolk", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?AnsweringBody.=Department+of+Health&answer.previousAnswerVersion.answeringMemberConstituency=Mid+Norfolk", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health&answer.previousAnswerVersion.answeringMemberConstituency=Mid+Norfolk&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&AnsweringBody.=Department+of+Health&answer.previousAnswerVersion.answeringMemberConstituency=Mid+Norfolk", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health&answer.previousAnswerVersion.answeringMemberConstituency=Mid+Norfolk", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health&answer.previousAnswerVersion.answeringMemberConstituency=Mid+Norfolk", "items" : [{"_about" : "http://data.parliament.uk/resources/522126", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/522126/answer", "answerText" : {"_value" : "<p>There are <del class=\"ministerial\">two<\/del> <ins class=\"ministerial\">three <\/ins>human papilloma virus vaccines licensed in the European Union: Cervarix<ins class=\"ministerial\">,<\/ins> <del class=\"ministerial\">and<\/del> <ins class=\"ministerial\">Gardasil and <\/ins>Gardasil 9. These products are licensed centrally throughout Europe by the European Commission via the European Medicines Agency (EMA). Applicants for centrally authorised products are required to submit all relevant supporting clinical trials data, whether published or not, to the EMA directly and not to the Medicines and Healthcare products Regulatory Agency.<\/p><p> <\/p><p>Under current medicines legislation, the EMA database registers all EU-approved clinical trials of investigational medicinal products. Since March 2011 this information has been publicly accessible through the EU Clinical Trials Register (except adult Phase 1 trials). The EU Clinical Trials Register includes all EU-conducted trials since May 2004 when the Clinical Trials Directive was implemented and can be found here:<\/p><p> <\/p><p><a href=\"https://www.clinicaltrialsregister.eu/ctr-search/search\" target=\"_blank\">https://www.clinicaltrialsregister.eu/ctr-search/search<\/a><\/p><p> <\/p><p>Furthermore since July 2014 clinical trial sponsors have been required to provide a summary of their trial results uploaded onto the EU Clinical Trials Register within one year of their trial completing. There is a two year programme of back-loading underway to provide summaries of trial results for all trials on the Register back to when the EudraCT database was initiated in May 2004.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2016-06-07", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/522126/answer/previousversion/2228", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2016-06-07T10:57:37.313Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2016-06-13T10:14:27.603Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2016-05-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, whether the Medicines and Healthcare Products Regulatory Agency holds any clinical trial data for HPV vaccines which is not in the public domain.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
      }
      , "tablingMemberConstituency" : {"_value" : "Denton and Reddish"}
      , "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"}
      ], "uin" : "38833"}
    , {"_about" : "http://data.parliament.uk/resources/431742", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/431742/answer", "answerText" : {"_value" : "<p>NHS England was formed in April 2013.<\/p><br /><p>The table below shows actual expenditure by clinical commissioning groups (CCGs) on mental health in 2013/14 and 2014/15 and forecast spend in 2015/16. This does not include spending on mental health services directly commissioned by NHS England.<\/p><p>Total actual expenditure by on mental health by CCGs across all providers for 2013/14 and 2014/15 and the total forecast expenditure for 2015/16<\/p><br /><table><tbody><tr><td><p>2013/14 actual spend (£ <ins class=\"ministerial\">billion <\/ins><del class=\"ministerial\">million<\/del>)<\/p><\/td><td><p>2014/15 actual spend (£ <ins class=\"ministerial\">billion<\/ins><del class=\"ministerial\">million<\/del>)<\/p><\/td><td><p>2015/16 forecast spend (£ <ins class=\"ministerial\">billion <\/ins><del class=\"ministerial\">million<\/del>)<\/p><\/td><\/tr><tr><td><p>9.6<\/p><\/td><td><p>10.1<\/p><\/td><td><p>10.6<\/p><\/td><\/tr><\/tbody><\/table><br /><p><em>Source:<\/em> NHS England<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-11-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/431742/answer/previousversion/32352", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2015-11-26T16:25:03.7Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-12-02T14:16:07.33Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-11-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Mental Health Services: Per Capita Costs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how much NHS England spent per head on mental health in each year since 2008.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
      }
      , "tablingMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
      , "tablingMemberPrinted" : [{"_value" : "Dr   Poulter"}
      ], "uin" : "17404"}
    , {"_about" : "http://data.parliament.uk/resources/224735", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/224735/answer", "answerText" : {"_value" : "<p>Clinical commissioning group (CCG) funding has not been decided beyond 2015/16. Notified revenue allocations and per capita allocations for Cumbria CCG are:<\/p><p> <\/p><p> <\/p><p> <\/p><table><tbody><tr><td><p>Year<\/p><\/td><td><p>Allocation £000<\/p><\/td><td><p>Per capita £<\/p><\/td><\/tr><tr><td><p>2013/14<\/p><\/td><td><p><del class=\"ministerial\">692,122<\/del><\/p><p><ins class=\"ministerial\">663,133<\/ins><\/p><\/td><td><p><del class=\"ministerial\">1,330<\/del><\/p><p><ins class=\"ministerial\">1,274<\/ins><\/p><\/td><\/tr><tr><td><p>2014/15<\/p><\/td><td><p>677,324<\/p><\/td><td><p>1,299<\/p><\/td><\/tr><tr><td><p>2015/16<\/p><\/td><td><p>685,654<\/p><\/td><td><p>1,313<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p> <\/p><p>These figures exclude running cost and Better Care Fund allocations.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2015-03-06", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/224735/answer/previousversion/48371", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2015-03-06T14:39:07.327Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-03-19T18:02:16.817Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2015-03-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Clinical Commissioning Groups: Cumbria"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what funding (a) in total and (b) per capita has been allocated for Cumbria Clinical Commissioning Group for each year from 2013-14 to 2019-20.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1503", "label" : {"_value" : "Biography information for Mr Jamie Reed"}
      }
      , "tablingMemberConstituency" : {"_value" : "Copeland"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Jamie Reed"}
      ], "uin" : "226114"}
    , {"_about" : "http://data.parliament.uk/resources/101565", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/101565/answer", "answerText" : {"_value" : "<p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) supports the National Health Service to improve patient access to clinically and cost effective medicines in a number of ways:<\/p><p> <\/p><p> <\/p><p> <\/p><p>- by making medicines more affordable. The PPRS limits growth in the vast majority of spend on branded medicines with industry making payments for spend above the agreed limit;<\/p><p> <\/p><p> <\/p><p> <\/p><p>- by providing stability and predictability to the Government and the pharmaceutical industry thereby promoting a strong and profitable pharmaceutical industry which encourages innovation and the development of high value treatments; and<\/p><p> <\/p><p> <\/p><p> <\/p><p>- by a number of agreed measure to improve access to branded medicines commensurate with the outcomes they offer patients.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Sales of new products are exempt from PPRS payments though still included in the overall limit on growth and the payments made by industry as a whole. This creates a strong in-built incentive in the scheme for companies to innovate.<\/p><p> <\/p><p><br> In respect of England, the anticipated PPRS payments for 2014-15 were passed on to NHS England through the Mandate and as such were included within commissioner allocations. In addition, an indicative budget for NHS England for 2015-16 was set on the basis of, amongst other things, the PPRS payment forecast available in 2014. <br> <br> In accordance with normal Government accounting rules and the agreed PPRS, there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients\u2019 health and care. As part of this, following discussion with the Department, NHS England and the Association of the British Pharmaceutical Industry are now pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.<\/p><p> <\/p><p> <\/p><p> <\/p><p>More generally, the Government\u2019s <em>Strategy for UK Life Sciences<\/em> sets out an ambitious long-term programme of action to improve the wider environment for pharmaceutical innovation and make the United Kingdom a world-leading place for life sciences investment. The Strategy has delivered £2 billion in industry and private sector investment in the United Kingdom since it was launched in December 2011.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-11-04", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "212417"}
        , {"_value" : "212419"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/101565/answer/previousversion/25830", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-11-04T17:36:41.174264Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pharmaceutical Price Regulation Scheme"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, if he will take steps to ensure that payments made by the pharmaceutical industry under the current Pharmaceutical Price Regulation Scheme are used to NHS England to achieve measurable and improved access to new medicines by NHS patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Lancashire"}
      , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
      ], "uin" : "212418"}
    , {"_about" : "http://data.parliament.uk/resources/101575", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/101575/answer", "answerText" : {"_value" : "<p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) supports the National Health Service to improve patient access to clinically and cost effective medicines in a number of ways:<\/p><p> <\/p><p> <\/p><p> <\/p><p>- by making medicines more affordable. The PPRS limits growth in the vast majority of spend on branded medicines with industry making payments for spend above the agreed limit;<\/p><p> <\/p><p> <\/p><p> <\/p><p>- by providing stability and predictability to the Government and the pharmaceutical industry thereby promoting a strong and profitable pharmaceutical industry which encourages innovation and the development of high value treatments; and<\/p><p> <\/p><p> <\/p><p> <\/p><p>- by a number of agreed measure to improve access to branded medicines commensurate with the outcomes they offer patients.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Sales of new products are exempt from PPRS payments though still included in the overall limit on growth and the payments made by industry as a whole. This creates a strong in-built incentive in the scheme for companies to innovate.<\/p><p> <\/p><p><br> In respect of England, the anticipated PPRS payments for 2014-15 were passed on to NHS England through the Mandate and as such were included within commissioner allocations. In addition, an indicative budget for NHS England for 2015-16 was set on the basis of, amongst other things, the PPRS payment forecast available in 2014. <br> <br> In accordance with normal Government accounting rules and the agreed PPRS, there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients\u2019 health and care. As part of this, following discussion with the Department, NHS England and the Association of the British Pharmaceutical Industry are now pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.<\/p><p> <\/p><p> <\/p><p> <\/p><p>More generally, the Government\u2019s <em>Strategy for UK Life Sciences<\/em> sets out an ambitious long-term programme of action to improve the wider environment for pharmaceutical innovation and make the United Kingdom a world-leading place for life sciences investment. The Strategy has delivered £2 billion in industry and private sector investment in the United Kingdom since it was launched in December 2011.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-11-04", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "212418"}
        , {"_value" : "212419"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/101575/answer/previousversion/25828", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-11-04T17:36:41.0482809Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pharmaceutical Price Regulation Scheme"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what discussions (a) he and (b) officials in his Department have had on ensuring that the payments made by the pharmaceutical industry under the current Pharmaceutical Price Regulation Scheme will be used to improve access to innovative medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Lancashire"}
      , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
      ], "uin" : "212417"}
    , {"_about" : "http://data.parliament.uk/resources/101583", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/101583/answer", "answerText" : {"_value" : "<p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) supports the National Health Service to improve patient access to clinically and cost effective medicines in a number of ways:<\/p><p> <\/p><p> <\/p><p> <\/p><p>- by making medicines more affordable. The PPRS limits growth in the vast majority of spend on branded medicines with industry making payments for spend above the agreed limit;<\/p><p> <\/p><p> <\/p><p> <\/p><p>- by providing stability and predictability to the Government and the pharmaceutical industry thereby promoting a strong and profitable pharmaceutical industry which encourages innovation and the development of high value treatments; and<\/p><p> <\/p><p> <\/p><p> <\/p><p>- by a number of agreed measure to improve access to branded medicines commensurate with the outcomes they offer patients.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Sales of new products are exempt from PPRS payments though still included in the overall limit on growth and the payments made by industry as a whole. This creates a strong in-built incentive in the scheme for companies to innovate.<\/p><p> <\/p><p><br> In respect of England, the anticipated PPRS payments for 2014-15 were passed on to NHS England through the Mandate and as such were included within commissioner allocations. In addition, an indicative budget for NHS England for 2015-16 was set on the basis of, amongst other things, the PPRS payment forecast available in 2014. <br> <br> In accordance with normal Government accounting rules and the agreed PPRS, there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients\u2019 health and care. As part of this, following discussion with the Department, NHS England and the Association of the British Pharmaceutical Industry are now pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.<\/p><p> <\/p><p> <\/p><p> <\/p><p>More generally, the Government\u2019s <em>Strategy for UK Life Sciences<\/em> sets out an ambitious long-term programme of action to improve the wider environment for pharmaceutical innovation and make the United Kingdom a world-leading place for life sciences investment. The Strategy has delivered £2 billion in industry and private sector investment in the United Kingdom since it was launched in December 2011.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-11-04", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "212417"}
        , {"_value" : "212418"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/101583/answer/previousversion/25832", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-11-04T17:36:41.2886778Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pharmaceutical Price Regulation Scheme"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, if he will make it his policy to use the Pharmaceutical Price Regulation Scheme to make the UK (a) a global leader in providing patients access to the most innovative appropriate medicines and (b) an attractive place for pharmaceutical companies to locate and invest.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
      }
      , "tablingMemberConstituency" : {"_value" : "West Lancashire"}
      , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
      ], "uin" : "212419"}
    , {"_about" : "http://data.parliament.uk/resources/100885", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/100885/answer", "answerText" : {"_value" : "<p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p><p> <\/p><p> <\/p><p> <\/p><p><em>£ million<\/em><\/p><p> <\/p><table><tbody><tr><td> <\/td><td><p>2009-10<\/p><\/td><td><p>2010-11<\/p><\/td><td><p>2011-12<\/p><\/td><td><p>2012-13<\/p><\/td><td><p>2013-14<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Asthma<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p><del class=\"ministerial\">22.2 <\/del><ins class=\"ministerial\">6.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.5 <\/del><ins class=\"ministerial\">5.3<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.2<\/del><ins class=\"ministerial\"> 4.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.4<\/del><ins class=\"ministerial\"> 3.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">18.8<\/del><ins class=\"ministerial\"> 5.4<\/ins><\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.3<\/p><\/td><td><p>1.5<\/p><\/td><td><p>0.8<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>2.6<\/p><\/td><td><p>3.4<\/p><\/td><td><p>2.4<\/p><\/td><td><p>3.4<\/p><\/td><td><p>3.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p><del class=\"ministerial\">24.8<\/del><ins class=\"ministerial\"> 9.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">21.0<\/del><ins class=\"ministerial\"> 8.8<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.9<\/del><ins class=\"ministerial\"> 7.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">24.3 <\/del><ins class=\"ministerial\">8.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">23.4<\/del> <ins class=\"ministerial\">10.0<\/ins><\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Motor Neurone Research<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>7.0<\/p><\/td><td><p>7.5<\/p><\/td><td><p>4.2<\/p><\/td><td><p>4.1<\/p><\/td><td><p>3.6<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.5<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>7.3<\/p><\/td><td><p>7.8<\/p><\/td><td><p>5.0<\/p><\/td><td><p>5.5<\/p><\/td><td><p>5.1<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Osteoporosis<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>6.2<\/p><\/td><td><p>5.4<\/p><\/td><td><p>5.1<\/p><\/td><td><p>4.6<\/p><\/td><td><p>5.9<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.3<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.8<\/p><\/td><td><p>1.3<\/p><\/td><td><p>1.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>6.5<\/p><\/td><td><p>6.1<\/p><\/td><td><p>6.0<\/p><\/td><td><p>6.3<\/p><\/td><td><p>8.7<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p> <\/p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100885/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:29.113Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Asthma: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leicester West"}
      , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
      ], "uin" : "211885"}
    , {"_about" : "http://data.parliament.uk/resources/100887", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/100887/answer", "answerText" : {"_value" : "<p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p><p> <\/p><p> <\/p><p> <\/p><p><em>£ million<\/em><\/p><p> <\/p><table><tbody><tr><td> <\/td><td><p>2009-10<\/p><\/td><td><p>2010-11<\/p><\/td><td><p>2011-12<\/p><\/td><td><p>2012-13<\/p><\/td><td><p>2013-14<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Asthma<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p><del class=\"ministerial\">22.2 <\/del><ins class=\"ministerial\">6.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.5 <\/del><ins class=\"ministerial\">5.3<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.2<\/del><ins class=\"ministerial\"> 4.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.4<\/del><ins class=\"ministerial\"> 3.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">18.8<\/del><ins class=\"ministerial\"> 5.4<\/ins><\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.3<\/p><\/td><td><p>1.5<\/p><\/td><td><p>0.8<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>2.6<\/p><\/td><td><p>3.4<\/p><\/td><td><p>2.4<\/p><\/td><td><p>3.4<\/p><\/td><td><p>3.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p><del class=\"ministerial\">24.8<\/del><ins class=\"ministerial\"> 9.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">21.0<\/del><ins class=\"ministerial\"> 8.8<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.9<\/del><ins class=\"ministerial\"> 7.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">24.3 <\/del><ins class=\"ministerial\">8.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">23.4<\/del> <ins class=\"ministerial\">10.0<\/ins><\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Motor Neurone Research<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>7.0<\/p><\/td><td><p>7.5<\/p><\/td><td><p>4.2<\/p><\/td><td><p>4.1<\/p><\/td><td><p>3.6<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.5<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>7.3<\/p><\/td><td><p>7.8<\/p><\/td><td><p>5.0<\/p><\/td><td><p>5.5<\/p><\/td><td><p>5.1<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Osteoporosis<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>6.2<\/p><\/td><td><p>5.4<\/p><\/td><td><p>5.1<\/p><\/td><td><p>4.6<\/p><\/td><td><p>5.9<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.3<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.8<\/p><\/td><td><p>1.3<\/p><\/td><td><p>1.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>6.5<\/p><\/td><td><p>6.1<\/p><\/td><td><p>6.0<\/p><\/td><td><p>6.3<\/p><\/td><td><p>8.7<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p> <\/p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100887/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Asthma"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leicester West"}
      , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
      ], "uin" : "211918"}
    , {"_about" : "http://data.parliament.uk/resources/100721", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/100721/answer", "answerText" : {"_value" : "<p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p><p> <\/p><p> <\/p><p> <\/p><p><em>£ million<\/em><\/p><p> <\/p><table><tbody><tr><td> <\/td><td><p>2009-10<\/p><\/td><td><p>2010-11<\/p><\/td><td><p>2011-12<\/p><\/td><td><p>2012-13<\/p><\/td><td><p>2013-14<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Asthma<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p><del class=\"ministerial\">22.2 <\/del><ins class=\"ministerial\">6.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.5 <\/del><ins class=\"ministerial\">5.3<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.2<\/del><ins class=\"ministerial\"> 4.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.4<\/del><ins class=\"ministerial\"> 3.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">18.8<\/del><ins class=\"ministerial\"> 5.4<\/ins><\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.3<\/p><\/td><td><p>1.5<\/p><\/td><td><p>0.8<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>2.6<\/p><\/td><td><p>3.4<\/p><\/td><td><p>2.4<\/p><\/td><td><p>3.4<\/p><\/td><td><p>3.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p><del class=\"ministerial\">24.8<\/del><ins class=\"ministerial\"> 9.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">21.0<\/del><ins class=\"ministerial\"> 8.8<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.9<\/del><ins class=\"ministerial\"> 7.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">24.3 <\/del><ins class=\"ministerial\">8.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">23.4<\/del> <ins class=\"ministerial\">10.0<\/ins><\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Motor Neurone Research<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>7.0<\/p><\/td><td><p>7.5<\/p><\/td><td><p>4.2<\/p><\/td><td><p>4.1<\/p><\/td><td><p>3.6<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.5<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>7.3<\/p><\/td><td><p>7.8<\/p><\/td><td><p>5.0<\/p><\/td><td><p>5.5<\/p><\/td><td><p>5.1<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Osteoporosis<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>6.2<\/p><\/td><td><p>5.4<\/p><\/td><td><p>5.1<\/p><\/td><td><p>4.6<\/p><\/td><td><p>5.9<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.3<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.8<\/p><\/td><td><p>1.3<\/p><\/td><td><p>1.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>6.5<\/p><\/td><td><p>6.1<\/p><\/td><td><p>6.0<\/p><\/td><td><p>6.3<\/p><\/td><td><p>8.7<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p> <\/p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100721/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Osteoporosis"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leicester West"}
      , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
      ], "uin" : "211732"}
    , {"_about" : "http://data.parliament.uk/resources/100723", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/100723/answer", "answerText" : {"_value" : "<p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p><p> <\/p><p> <\/p><p> <\/p><p><em>£ million<\/em><\/p><p> <\/p><table><tbody><tr><td> <\/td><td><p>2009-10<\/p><\/td><td><p>2010-11<\/p><\/td><td><p>2011-12<\/p><\/td><td><p>2012-13<\/p><\/td><td><p>2013-14<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Asthma<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p><del class=\"ministerial\">22.2 <\/del><ins class=\"ministerial\">6.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.5 <\/del><ins class=\"ministerial\">5.3<\/ins><\/p><\/td><td><p><del class=\"ministerial\">17.2<\/del><ins class=\"ministerial\"> 4.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.4<\/del><ins class=\"ministerial\"> 3.6<\/ins><\/p><\/td><td><p><del class=\"ministerial\">18.8<\/del><ins class=\"ministerial\"> 5.4<\/ins><\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.3<\/p><\/td><td><p>1.5<\/p><\/td><td><p>0.8<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>2.6<\/p><\/td><td><p>3.4<\/p><\/td><td><p>2.4<\/p><\/td><td><p>3.4<\/p><\/td><td><p>3.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p><del class=\"ministerial\">24.8<\/del><ins class=\"ministerial\"> 9.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">21.0<\/del><ins class=\"ministerial\"> 8.8<\/ins><\/p><\/td><td><p><del class=\"ministerial\">19.9<\/del><ins class=\"ministerial\"> 7.2<\/ins><\/p><\/td><td><p><del class=\"ministerial\">24.3 <\/del><ins class=\"ministerial\">8.5<\/ins><\/p><\/td><td><p><del class=\"ministerial\">23.4<\/del> <ins class=\"ministerial\">10.0<\/ins><\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Motor Neurone Research<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>7.0<\/p><\/td><td><p>7.5<\/p><\/td><td><p>4.2<\/p><\/td><td><p>4.1<\/p><\/td><td><p>3.6<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.2<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.5<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>7.3<\/p><\/td><td><p>7.8<\/p><\/td><td><p>5.0<\/p><\/td><td><p>5.5<\/p><\/td><td><p>5.1<\/p><\/td><\/tr><tr><td colspan=\"6\"><p>Osteoporosis<\/p><\/td><\/tr><tr><td><p>Medical Research Council<\/p><\/td><td><p>6.2<\/p><\/td><td><p>5.4<\/p><\/td><td><p>5.1<\/p><\/td><td><p>4.6<\/p><\/td><td><p>5.9<\/p><\/td><\/tr><tr><td><p>Other Research Councils and Innovate UK<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.0<\/p><\/td><td><p>0.1<\/p><\/td><td><p>0.4<\/p><\/td><td><p>1.0<\/p><\/td><\/tr><tr><td><p>National Institute for Health Research<\/p><\/td><td><p>0.3<\/p><\/td><td><p>0.7<\/p><\/td><td><p>0.8<\/p><\/td><td><p>1.3<\/p><\/td><td><p>1.8<\/p><\/td><\/tr><tr><td><p>Total<\/p><\/td><td><p>6.5<\/p><\/td><td><p>6.1<\/p><\/td><td><p>6.0<\/p><\/td><td><p>6.3<\/p><\/td><td><p>8.7<\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p> <\/p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p><p> <\/p><p> <\/p><p> <\/p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
        }
        , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100723/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
          }
          , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
          , "answeringMemberPrinted" : {"_value" : "George Freeman"}
        }
        , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
        ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Motor Neurone Disease: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leicester West"}
      , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
      ], "uin" : "211734"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&AnsweringBody.=Department+of+Health&answer.previousAnswerVersion.answeringMemberConstituency=Mid+Norfolk", "page" : 0, "startIndex" : 1, "totalResults" : 15, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}